Top

Clinical Reviews in Allergy & Immunology

Published in:

01-12-2012

To B or Not to B the Conductor of Rheumatoid Arthritis Orchestra

Authors: Rita A. Moura, Luis Graca, João E. Fonseca

Published in: Clinical Reviews in Allergy & Immunology | Issue 3/2012

Abstract

Rheumatoid arthritis (RA) is a chronic, systemic immune-mediated inflammatory disorder that mainly targets the joints. Several lines of evidence have pointed to B cell function as a critical factor in the development of RA. B cells play several roles in the pathogenesis of RA, such as autoantibody production, antigen presentation and T cell activation, cytokine release, and ectopic lymphoid organogenesis. The success of B cell depletion therapy in RA further supports the relevance of these cells in RA progression. In addition, recent studies have also highlighted the B cell role in the first weeks of RA onset. The present article is a review focused in the immunopathogenic B cell-dependent mechanisms associated with RA development and chronicity and the importance of the recent discoveries documented in untreated very early RA patients with less than 6 weeks of disease duration.

Scott DL, Wolfe F, Huizinga TW (2010) Rheumatoid arthritis. Lancet 376:1094–1108PubMedCrossRef

Moura RA, Weinmann P, Pereira PA et al (2010) Alterations on peripheral blood B-cell subpopulations in very early arthritis patients. Rheumatology (Oxford) 49:1082–1092CrossRef

Moura RA, Cascao R, Perpetuo I et al (2011) Cytokine pattern in very early rheumatoid arthritis favours B-cell activation and survival. Rheumatology (Oxford) 50:278–282CrossRef

Cascao R, Moura RA, Perpetuo I et al (2010) Identification of a cytokine network sustaining neutrophil and Th17 activation in untreated early rheumatoid arthritis. Arthritis Res Ther 12:R196PubMedCrossRef

de la Torre I, Moura RA, Leandro MJ, Edwards J, Cambridge G (2010) B-cell-activating factor receptor expression on naive and memory B cells: relationship with relapse in patients with rheumatoid arthritis following B-cell depletion therapy. Ann Rheum Dis 69:2181–2188PubMedCrossRef

Waaler E (1940) On the occurrence of a factor in human serum activating the specific agglutination of sheep red corpuscles. Acta Pathol Microbiol Scand 17:172–188CrossRef

Burkhardt H, Koller T, Engstrom A et al (2002) Epitope-specific recognition of type II collagen by rheumatoid arthritis antibodies is shared with recognition by antibodies that are arthritogenic in collagen-induced arthritis in the mouse. Arthritis Rheum 46:2339–2348PubMedCrossRef

Schaller M, Stohl W, Tan SM, Benoit VM, Hilbert DM, Ditzel HJ (2005) Raised levels of anti-glucose-6-phosphate isomerase IgG in serum and synovial fluid from patients with inflammatory arthritis. Ann Rheum Dis 64:743–749PubMedCrossRef

Hassfeld W, Steiner G, Graninger W, Witzmann G, Schweitzer H, Smolen JS (1993) Autoantibody to the nuclear antigen RA33: a marker for early rheumatoid arthritis. Br J Rheumatol 32:199–203PubMedCrossRef

10.

Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ (1998) Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 101:273–281PubMedCrossRef

11.

Angyal A, Egelston C, Kobezda T et al (2010) Development of proteoglycan-induced arthritis depends on T cell-supported autoantibody production, but does not involve significant influx of T cells into the joints. Arthritis Res Ther 12:R44PubMedCrossRef

12.

Wernick RM, Lipsky PE, Marban-Arcos E, Maliakkal JJ, Edelbaum D, Ziff M (1985) IgG and IgM rheumatoid factor synthesis in rheumatoid synovial membrane cell cultures. Arthritis Rheum 28:742–752PubMedCrossRef

13.

Edwards JC, Cambridge G (1998) Rheumatoid arthritis: the predictable effect of small immune complexes in which antibody is also antigen. Br J Rheumatol 37:126–130PubMedCrossRef

14.

Pai S, Pai L, Birkenfeldt R (1998) Correlation of serum IgA rheumatoid factor levels with disease severity in rheumatoid arthritis. Scand J Rheumatol 27:252–256PubMedCrossRef

15.

Tanimoto K, Cooper NR, Johnson JS, Vaughan JH (1975) Complement fixation by rheumatoid factor. J Clin Invest 55:437–445PubMedCrossRef

16.

Nell VP, Machold KP, Stamm TA et al (2005) Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis 64:1731–1736PubMedCrossRef

17.

Borretzen M, Chapman C, Natvig JB, Thompson KM (1997) Differences in mutational patterns between rheumatoid factors in health and disease are related to variable heavy chain family and germ-line gene usage. Eur J Immunol 27:735–741PubMedCrossRef

18.

Thompson KM, Randen I, Borretzen M, Forre O, Natvig JB (1994) Variable region gene usage of human monoclonal rheumatoid factors derived from healthy donors following immunization. Eur J Immunol 24:1771–1778PubMedCrossRef

19.

Jonsson T, Arinbjarnarson S, Thorsteinsson J et al (1995) Raised IgA rheumatoid factor (RF) but not IgM RF or IgG RF is associated with extra-articular manifestations in rheumatoid arthritis. Scand J Rheumatol 24:372–375PubMedCrossRef

20.

Mannik M, Nardella FA (1985) IgG rheumatoid factors and self-association of these antibodies. Clin Rheum Dis 11:551–572PubMed

21.

Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRef

22.

Aletaha D, Neogi T, Silman AJ et al (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569–2581PubMedCrossRef

23.

Schellekens GA, Visser H, de Jong BA et al (2000) The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 43:155–163PubMedCrossRef

24.

Girbal-Neuhauser E, Durieux JJ, Arnaud M et al (1999) The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J Immunol 162:585–594PubMed

25.

Reparon-Schuijt CC, van Esch WJ, van Kooten C et al (2001) Secretion of anti-citrulline-containing peptide antibody by B lymphocytes in rheumatoid arthritis. Arthritis Rheum 44:41–47PubMedCrossRef

26.

Vossenaar ER, Zendman AJ, van Venrooij WJ, Pruijn GJ (2003) PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays 25:1106–1118PubMedCrossRef

27.

Song YW, Kang EH (2010) Autoantibodies in rheumatoid arthritis: rheumatoid factors and anticitrullinated protein antibodies. QJM 103:139–146PubMedCrossRef

28.

Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E et al (2001) The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J Immunol 166:4177–4184PubMed

29.

Zhao X, Okeke NL, Sharpe O et al (2008) Circulating immune complexes contain citrullinated fibrinogen in rheumatoid arthritis. Arthritis Res Ther 10:R94PubMedCrossRef

30.

van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW (2005) Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 7:R949–958PubMedCrossRef

31.

Uysal H, Bockermann R, Nandakumar KS et al (2009) Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis. J Exp Med 206:449–462PubMedCrossRef

32.

van der Linden MP, van der Woude D, Ioan-Facsinay A et al (2009) Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis Rheum 60:2232–2241PubMedCrossRef

33.

van Oosterhout M, Bajema I, Levarht EW, Toes RE, Huizinga TW, van Laar JM (2008) Differences in synovial tissue infiltrates between anti-cyclic citrullinated peptide-positive rheumatoid arthritis and anti-cyclic citrullinated peptide-negative rheumatoid arthritis. Arthritis Rheum 58:53–60PubMedCrossRef

34.

Syversen SW, Gaarder PI, Goll GL et al (2008) High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis 67:212–217PubMedCrossRef

35.

Breitfeld D, Ohl L, Kremmer E et al (2000) Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J Exp Med 192:1545–1552PubMedCrossRef

36.

Schroder AE, Greiner A, Seyfert C, Berek C (1996) Differentiation of B cells in the nonlymphoid tissue of the synovial membrane of patients with rheumatoid arthritis. Proc Natl Acad Sci U S A 93:221–225PubMedCrossRef

37.

Takemura S, Braun A, Crowson C et al (2001) Lymphoid neogenesis in rheumatoid synovitis. J Immunol 167:1072–1080PubMed

38.

Humby F, Bombardieri M, Manzo A et al (2009) Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium. PLoS Med 6:e1PubMedCrossRef

39.

Fonseca JE, Canhao H, Resende C et al (2000) Histology of the synovial tissue: value of semiquantitative analysis for the prediction of joint erosions in rheumatoid arthritis. Clin Exp Rheumatol 18:559–564PubMedCrossRef

40.

Manzo A, Vitolo B, Humby F et al (2008) Mature antigen-experienced T helper cells synthesize and secrete the B cell chemoattractant CXCL13 in the inflammatory environment of the rheumatoid joint. Arthritis Rheum 58:3377–3387PubMedCrossRef

41.

Kim KW, Cho ML, Kim HR et al (2007) Up-regulation of stromal cell-derived factor 1 (CXCL12) production in rheumatoid synovial fibroblasts through interactions with T lymphocytes: role of interleukin-17 and CD40L-CD40 interaction. Arthritis Rheum 56:1076–1086PubMedCrossRef

42.

Rennert PD, James D, Mackay F, Browning JL, Hochman PS (1998) Lymph node genesis is induced by signaling through the lymphotoxin beta receptor. Immunity 9:71–79PubMedCrossRef

43.

Cheema GS, Roschke V, Hilbert DM, Stohl W (2001) Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 44:1313–1319PubMedCrossRef

44.

Badr G, Borhis G, Lefevre EA et al (2008) BAFF enhances chemotaxis of primary human B cells: a particular synergy between BAFF and CXCL13 on memory B cells. Blood 111:2744–2754PubMedCrossRef

45.

Houssiau FA, Devogelaer JP, Van Damme J, de Deuxchaisnes CN, Van Snick J (1988) Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 31:784–788PubMedCrossRef

46.

Fonseca JE, Santos MJ, Canhao H, Choy E (2009) Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 8:538–542PubMedCrossRef

47.

Ettinger R, Sims GP, Fairhurst AM et al (2005) IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells. J Immunol 175:7867–7879PubMed

48.

Hickman-Brecks, C. L., Racz, J. L., Meyer, D. M., Labranche, T. P., Allen, P. M. (2010), Th17 cells can provide B cell help in autoantibody induced arthritis. J Autoimmun

49.

Kashiwakuma D, Suto A, Hiramatsu Y et al (2010) B and T lymphocyte attenuator suppresses IL-21 production from follicular Th cells and subsequent humoral immune responses. J Immunol 185:2730–2736PubMedCrossRef

50.

Lanzavecchia A (1985) Antigen-specific interaction between T and B cells. Nature 314:537–539PubMedCrossRef

51.

Rivera A, Chen CC, Ron N, Dougherty JP, Ron Y (2001) Role of B cells as antigen-presenting cells in vivo revisited: antigen-specific B cells are essential for T cell expansion in lymph nodes and for systemic T cell responses to low antigen concentrations. Int Immunol 13:1583–1593PubMedCrossRef

52.

Roosnek E, Lanzavecchia A (1991) Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells. J Exp Med 173:487–489PubMedCrossRef

53.

Tighe H, Chen PP, Tucker R et al (1993) Function of B cells expressing a human immunoglobulin M rheumatoid factor autoantibody in transgenic mice. J Exp Med 177:109–118PubMedCrossRef

54.

O'Neill SK, Shlomchik MJ, Glant TT, Cao Y, Doodes PD, Finnegan A (2005) Antigen-specific B cells are required as APCs and autoantibody-producing cells for induction of severe autoimmune arthritis. J Immunol 174:3781–3788PubMed

55.

Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM (2001) T cell activation in rheumatoid synovium is B cell dependent. J Immunol 167:4710–4718PubMed

56.

Hamel KM, Cao Y, Ashaye S et al (2011) B cell depletion enhances T regulatory cell activity essential in the suppression of arthritis. J Immunol 187:4900–4906PubMedCrossRef

57.

Duarte J, Agua-Doce A, Oliveira VG, Fonseca JE, Graca L (2010) Modulation of IL-17 and Foxp3 expression in the prevention of autoimmune arthritis in mice. PLoS One 5:e10558PubMedCrossRef

58.

Harrington LE, Hatton RD, Mangan PR et al (2005) Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6:1123–1132PubMedCrossRef

59.

Lubberts E, Koenders MI, Oppers-Walgreen B et al (2004) Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 50:650–659PubMedCrossRef

60.

Chabaud M, Durand JM, Buchs N et al (1999) Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 42:963–970PubMedCrossRef

61.

Hsu HC, Yang P, Wang J et al (2008) Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol 9:166–175PubMedCrossRef

62.

Xie S, Li J, Wang JH et al (2010) IL-17 activates the canonical NF-kappaB signaling pathway in autoimmune B cells of BXD2 mice to upregulate the expression of regulators of G-protein signaling 16. J Immunol 184:2289–2296PubMedCrossRef

63.

Lai Kwan Lam Q, King Hung Ko O, Zheng BJ, Lu L (2008) Local BAFF gene silencing suppresses Th17-cell generation and ameliorates autoimmune arthritis. Proc Natl Acad Sci U S A 105:14993–14998PubMedCrossRef

64.

Mitsdoerffer M, Lee Y, Jager A et al (2010) Proinflammatory T helper type 17 cells are effective B-cell helpers. Proc Natl Acad Sci U S A 107:14292–14297PubMedCrossRef

65.

Takagi R, Higashi T, Hashimoto K et al (2008) B cell chemoattractant CXCL13 is preferentially expressed by human Th17 cell clones. J Immunol 181:186–189PubMed

66.

Kouskoff V, Korganow AS, Duchatelle V, Degott C, Benoist C, Mathis D (1996) Organ-specific disease provoked by systemic autoimmunity. Cell 87:811–822PubMedCrossRef

67.

Korganow AS, Ji H, Mangialaio S et al (1999) From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity 10:451–461PubMedCrossRef

68.

Wu HJ, Ivanov II, Darce J et al (2010) Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 32:815–827PubMedCrossRef

69.

Raposo BR, Rodrigues-Santos P, Carvalheiro H et al (2010) Monoclonal anti-CD8 therapy induces disease amelioration in the K/BxN mouse model of spontaneous chronic polyarthritis. Arthritis Rheum 62:2953–2962PubMedCrossRef

70.

Sakaguchi N, Takahashi T, Hata H et al (2003) Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature 426:454–460PubMedCrossRef

71.

Ehinger M, Vestberg M, Johansson AC, Johannesson M, Svensson A, Holmdahl R (2001) Influence of CD4 or CD8 deficiency on collagen-induced arthritis. Immunology 103:291–300PubMedCrossRef

72.

Svensson L, Jirholt J, Holmdahl R, Jansson L (1998) B cell-deficient mice do not develop type II collagen-induced arthritis (CIA). Clin Exp Immunol 111:521–526PubMedCrossRef

73.

Behrens M, Smart M, Luckey D, Luthra H, Taneja V (2011) To B or not to B: role of B cells in pathogenesis of arthritis in HLA transgenic mice. J Autoimmun 37:95–103PubMedCrossRef

74.

Cragg MS, Walshe CA, Ivanov AO, Glennie MJ (2005) The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 8:140–174PubMedCrossRef

75.

Maloney DG, Grillo-Lopez AJ, White CA et al (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188–2195PubMed

76.

Leget GA, Czuczman MS (1998) Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol 10:548–551PubMedCrossRef

77.

Edwards JC, Cambridge G (2001) Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 40:205–211CrossRef

78.

Leandro MJ, Edwards JC, Cambridge G (2002) Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 61:883–888PubMedCrossRef

79.

Edwards JC, Szczepanski L, Szechinski J et al (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572–2581PubMedCrossRef

80.

Emery P, Fleischmann R, Filipowicz-Sosnowska A et al (2006) The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54:1390–1400PubMedCrossRef

81.

Weinblatt ME, Kremer JM, Bankhurst AD et al (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340:253–259PubMedCrossRef

82.

Lipsky PE, van der Heijde DM, St Clair EW et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343:1594–1602PubMedCrossRef

83.

Weinblatt ME, Keystone EC, Furst DE et al (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48:35–45PubMedCrossRef

84.

Cohen SB, Emery P, Greenwald MW et al (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54:2793–2806PubMedCrossRef

85.

Edwards, J. C., Leandro, M. J., Cambridge, G. (2004), B lymphocyte depletion therapy with rituximab in rheumatoid arthritis. Rheum Dis Clin North Am. 30, 393-403, viii

86.

Roll P, Dorner T, Tony HP (2008) Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum 58:1566–1575PubMedCrossRef

87.

Quartuccio L, Fabris M, Salvin S et al (2009) Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatology (Oxford) 48:1557–1559CrossRef

88.

Pyrpasopoulou A, Douma S, Triantafyllou A et al (2010) Response to rituximab and timeframe to relapse in rheumatoid arthritis patients: association with B-cell markers. Mol Diagn Ther 14:43–48PubMedCrossRef

89.

Cambridge G, Leandro MJ, Edwards JC et al (2003) Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 48:2146–2154PubMedCrossRef

90.

Leandro MJ, Cooper N, Cambridge G, Ehrenstein MR, Edwards JC (2007) Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy. Rheumatology (Oxford) 46:29–36CrossRef

91.

Teng YK, Levarht EW, Hashemi M et al (2007) Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. Arthritis Rheum 56:3909–3918PubMedCrossRef

92.

Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC (2006) Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 54:723–732PubMedCrossRef

93.

Mizoguchi A, Mizoguchi E, Smith RN, Preffer FI, Bhan AK (1997) Suppressive role of B cells in chronic colitis of T cell receptor alpha mutant mice. J Exp Med 186:1749–1756PubMedCrossRef

94.

Mizoguchi A, Mizoguchi E, Takedatsu H, Blumberg RS, Bhan AK (2002) Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 16:219–230PubMedCrossRef

95.

Mauri C, Gray D, Mushtaq N, Londei M (2003) Prevention of arthritis by interleukin 10-producing B cells. J Exp Med 197:489–501PubMedCrossRef

96.

Blair PA, Chavez-Rueda KA, Evans JG et al (2009) Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr mice. J Immunol 182:3492–3502PubMedCrossRef

97.

Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM (2002) B cells regulate autoimmunity by provision of IL-10. Nat Immunol 3:944–950PubMedCrossRef

98.

Lee JH, Noh J, Noh G, Choi WS, Cho S, Lee SS (2011) Allergen-specific transforming growth factor-beta-producing CD19+ CD5+ regulatory B-cell (Br3) responses in human late eczematous allergic reactions to cow's milk. J Interferon Cytokine Res 31:441–449PubMedCrossRef

99.

Amu S, Saunders SP, Kronenberg M, Mangan NE, Atzberger A, Fallon PG (2011) Regulatory B cells prevent and reverse allergic airway inflammation via FoxP3-positive T regulatory cells in a murine model. J Allergy Clin Immunol 125(1114–1124):e1118

100.

Carter NA, Vasconcellos R, Rosser EC et al (2011) Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells. J Immunol 186:5569–5579PubMedCrossRef

101.

Duddy M, Niino M, Adatia F et al (2007) Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol 178:6092–6099PubMed

102.

Bouaziz JD, Calbo S, Maho-Vaillant M et al (2010) IL-10 produced by activated human B cells regulates CD4(+) T-cell activation in vitro. Eur J Immunol 40:2686–2691PubMedCrossRef

103.

Blair PA, Norena LY, Flores-Borja F et al (2010) CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity 32:129–140PubMedCrossRef

104.

Iwata Y, Matsushita T, Horikawa M et al (2010) Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 117:530–541PubMedCrossRef

105.

Mackay F, Woodcock SA, Lawton P et al (1999) Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 190:1697–1710PubMedCrossRef

106.

Khare SD, Sarosi I, Xia XZ et al (2000) Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci U S A 97:3370–3375PubMedCrossRef

107.

Tan SM, Xu D, Roschke V et al (2003) Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum 48:982–992PubMedCrossRef

108.

Ettinger R, Sims GP, Robbins R et al (2007) IL-21 and BAFF/BLyS synergize in stimulating plasma cell differentiation from a unique population of human splenic memory B cells. J Immunol 178:2872–2882PubMed

109.

Doreau A, Belot A, Bastid J et al (2009) Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol 10:778–785PubMedCrossRef

110.

Litinskiy MB, Nardelli B, Hilbert DM et al (2002) DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 3:822–829PubMedCrossRef

111.

Belnoue E, Pihlgren M, McGaha TL et al (2008) APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood 111:2755–2764PubMedCrossRef

112.

Nakajima K, Itoh K, Nagatani K et al (2007) Expression of BAFF and BAFF-R in the synovial tissue of patients with rheumatoid arthritis. Scand J Rheumatol 36:365–372PubMedCrossRef

113.

Dong W, Li X, Liu H, Zhu P (2009) Infiltrations of plasma cells in synovium are highly associated with synovial fluid levels of APRIL in inflamed peripheral joints of rheumatoid arthritis. Rheumatol Int 29:801–806PubMedCrossRef

114.

Gross JA, Johnston J, Mudri S et al (2000) TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404:995–999PubMedCrossRef

115.

Kayagaki N, Yan M, Seshasayee D et al (2002) BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity 17:515–524PubMedCrossRef

116.

Tak PP, Thurlings RM, Rossier C et al (2008) Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum 58:61–72PubMedCrossRef

117.

Furie R, Petri M, Zamani O et al (2011) A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63:3918–3930PubMedCrossRef

118.

Muraguchi A, Hirano T, Tang B et al (1988) The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med 167:332–344PubMedCrossRef

119.

Roll, P., Muhammad, K., Schumann, M., et al. (2011), In vivo effect of the anti interleukin-6 receptor inhibitor tocilizumab on the B-cell compartment. Arthritis Rheum

120.

Kawashiri, S. Y., Kawakami, A., Iwamoto, N., et al. (2011), In rheumatoid arthritis patients treated with tocilizumab, the rate of clinical disease activity index (CDAI) remission at 24 weeks is superior in those with higher titers of IgM-rheumatoid factor at baseline. Mod Rheumatol

121.

Muhammad K, Roll P, Seibold T et al (2011) Impact of IL-6 receptor inhibition on human memory B cells in vivo: impaired somatic hypermutation in preswitch memory B cells and modulation of mutational targeting in memory B cells. Ann Rheum Dis 70:1507–1510PubMedCrossRef

Title: To B or Not to B the Conductor of Rheumatoid Arthritis Orchestra
Authors: Rita A. Moura
Luis Graca
João E. Fonseca
Publication date: 01-12-2012
Publisher: Humana Press Inc
Published in: Clinical Reviews in Allergy & Immunology / Issue 3/2012
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI: https://doi.org/10.1007/s12016-012-8318-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2012

The Immunophysiology and Apoptosis of Biliary Epithelial Cells: Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis

Antineutrophil Cytoplasmic Autoantibodies: How Are They Detected and What Is Their Use for Diagnosis, Classification and Follow-up?

The Long-Term Marriage Between Autoimmunity and Internal Medicine: A Homage to Manuel Carlos Dias

Impact of Hallmark Autoantibody Reactivity on Early Diagnosis in Scleroderma

Behçet Syndrome: Is It One Condition?

The Multiple Autoimmune Syndromes. A Clue for the Autoimmune Tautology

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials